The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2
JPY 670 Million (USD 4.2 Million1) Investment in a Critical Diagnostic Tool to Combat Leishmaniasis.
In addition, the GHIT Fund will invest in the following five screening projects for a total amount of approximately JPY 83 million (USD 0.5 million1):
1) Screening project against malaria by MMV and Daiichi Sankyo Co., Ltd.
2) Screening project against dengue and Zika by Eisai and Drugs for Neglected Diseases initiative (DNDi)
3) Screening project against Lassa fever by MMV and RIKEN
4) Screening project against Rift Valley fever by MMV and RIKEN
5) Screening project against Ebola and Marburg by MMV and RIKEN
